Details for New Drug Application (NDA): 205613
✉ Email this page to a colleague
The generic ingredient in UCERIS is budesonide. There is one drug master file entry for this compound. Forty suppliers are listed for this compound. Additional details are available on the budesonide profile page.
Summary for 205613
| Tradename: | UCERIS |
| Applicant: | Salix |
| Ingredient: | budesonide |
| Patents: | 0 |
Pharmacology for NDA: 205613
| Mechanism of Action | Corticosteroid Hormone Receptor Agonists |
Medical Subject Heading (MeSH) Categories for 205613
Suppliers and Packaging for NDA: 205613
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| UCERIS | budesonide | AEROSOL, FOAM;RECTAL | 205613 | NDA | Salix Pharmaceuticals, Inc. | 65649-651 | 65649-651-03 | 2 CANISTER in 1 CARTON (65649-651-03) / 1 AEROSOL, FOAM in 1 CANISTER (65649-651-02) |
| UCERIS | budesonide | AEROSOL, FOAM;RECTAL | 205613 | NDA | Oceanside Pharmaceuticals | 68682-658 | 68682-658-03 | 2 CANISTER in 1 CARTON (68682-658-03) / 1 AEROSOL, FOAM in 1 CANISTER (68682-658-02) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | AEROSOL, FOAM;RECTAL | Strength | 2MG/ACTUATION | ||||
| Approval Date: | Oct 7, 2014 | TE: | AB | RLD: | Yes | ||||
Expired US Patents for NDA 205613
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Salix | UCERIS | budesonide | AEROSOL, FOAM;RECTAL | 205613-001 | Oct 7, 2014 | ⤷ Start Trial | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription
